EVOEvotec SE

Nasdaq evotec.com


$ 4.53 $ -0.01 (-0.22 %)    

Friday, 14-Jun-2024 15:46:53 EDT
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 4.55
$ 4.52
$ 0.00 x 0
$ 0.00 x 0
$ 4.48 - $ 4.53
$ 4.44 - $ 13.49
52,224
na
805.13M
$ 0.97
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 evotec-joins-forces-with-inserm-and-lille-university-hospital-to-identify-key-mechanisms-in-obesity-and-metabolic-diseases

Partnership will expand Evotec's molecular patient database in the area of metabolic diseases and in particular obesity ...

 hc-wainwright--co-reiterates-buy-on-evotec-maintains-11-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Evotec (NASDAQ:EVO) with a Buy and maintains $11 price target.

 evotec-q1-eps-007-beats-010-estimate-sales-22669m-beat-22257m-estimate

Evotec (NASDAQ:EVO) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 35 p...

Core News & Articles

CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies...

 bayer-and-evotec-collaborate-to-advance-precision-cardiology-financial-terms-undisclosed

Bayer and the German-based life science company, Evotec, announced today that they have updated the focus of their strategic co...

 hc-wainwright--co-maintains-buy-on-evotec-lowers-price-target-to-11

HC Wainwright & Co. analyst Douglas Tsao maintains Evotec (NASDAQ:EVO) with a Buy and lowers the price target from $14 t...

 life-science-focused-evotec-shares-plunge-to-6-year-lows-on-gloomy-annual-forecast

Evotec undergoes a strategic shift for sustainable growth in 2024. Priority reset to optimize operations; expect double-digit r...

 evotec-variant-bio-announce-collaboration-agreement-to-identify-treatment-for-diseases-caused-by-fibrosis

Under the terms of the risk-sharing partnership, Evotec will receive undisclosed research funding and may receive pre-clinical ...